English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Reports of human clinical trials aiming at antigen-specific induction of T cell and antibody responses against non–small cell lung cancers (NSCLC) have started to surface within the last 5 years ([1][1]–[11][2]). In a large proportion of trials, the nature of the antigen(s) has not been

Immunogenic Targets in Non–Small Cell Lung Cancer: More Is More